Cipla

Cipla's One India business demonstrated strong growth, achieving a 15% year-on-year increase in Q4 FY26 and a 9% year-on-year growth for the full fiscal year, with revenues surpassing INR12,500 crores. This performance was driven by double-digit growth across Branded Prescription, Trade Generics, and Consumer Health segments. Key chronic therapies like Respiratory, Anti-diabetes, Cardiac, and Urology delivered strong double-digit market growth, with the chronic mix reaching 60% as per IQVIA MAT March '26. The company also expanded its presence in the IPM by adding 4 brands exceeding INR100 crores, bringing the total to 33 such brands.

The North America business reported an annual revenue of $780 million, with Q4 contributing $155 million. A significant milestone was the regulatory approval for the first AB-rated generic Ventolin with CGT from Cipla's US facility, with launch expected in the coming months. The company aims to achieve a $1 billion run rate in North America by the end of FY27, supported by a robust pipeline of 40-50 products to be filed over the next 3 years, including 12 first-to-files. Globally, the One Africa business grew 14% year-on-year in Q4, and EMEU operations scaled to over $400 million, showcasing diversified growth across geographies.

Cipla significantly enhanced its pipeline and portfolio through strategic initiatives. This included launching several differentiated products in core therapies and entering into collaborations with Eli Lilly for Yurpeak (obesity segment) and Mannkind Corporation for Afrezza India (rapid-acting inhaled insulin). The acquisition of Inzpera Healthcare further strengthened the pediatric and wellness product portfolio. The company is also focusing on complex generics, with 8 Peptides & Complex Generics assets already filed and 3 more planned for filing in the next 12-24 months, alongside investments in Oligonucleotide and two global biosimilar assets.

For FY26, Cipla reported a total revenue of INR28,163 crores and an EBITDA margin of 21%. Q4 FY26 revenue stood at INR6,541 crores with an EBITDA margin of 15.2%. The lower Q4 margin was attributed to planned investments in talent and manufacturing readiness, as well as some impact from geopolitical situations on operating expenses. The company's R&D spend for FY26 was INR1,974 crores, representing approximately 7% of revenue, reflecting increased investment in complex products. Cipla expects FY27 EBITDA margins to be in the range of 18.5% to 20%, with sequential improvement anticipated in the second half of the year, excluding any contribution from Lanreotide.

Cipla demonstrated strong regulatory compliance, with all three US FDA inspections at its Indian manufacturing facilities (Bommasandra, Sitec, and Medispray in Goa) resulting in VAI or NAI classifications during FY26. This achievement underscores the company's commitment to quality and operational excellence. Furthermore, Cipla is accelerating its AI-led transformation, aiming to become an AI-led pharma organization. This initiative focuses on broad-based implementation across functions like quality, regulatory, corporate, and R&D, with the goal of driving efficiency, productivity, and better decision-making.

As of March 31, 2026, Cipla maintained a healthy net cash equivalent balance of INR10,526 crores, with total debt (including lease liabilities) at INR614 crores. The company's ROIC for FY26 was 22.9%. Management highlighted a strategic focus on deploying capital towards accelerating the R&D pipeline, particularly in biosimilars, where they plan to build a pipeline of 6-8 in-house assets over the next 5-8 years. While open to limited in-licensing for near-term opportunities, the primary focus remains on differentiated specialty products for developed markets to ensure sustainable long-term growth.